fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Coronavirus lockdown avoided 700,000 cases in 50 days

Written by | 6 Aug 2020

Article written by Gary Finnegan China’s control measures during the first 50 days of the COVID-19 epidemic may have delayed the spread of the virus to cities outside… read more.

Smokers and COPD patients suffer more and die more from COVID-19

Written by | 29 Jul 2020

Article written by Bruce Sylvester. Current smokers and those with chronic obstructive pulmonary disease COPD suffer greater COVID-19 severity and greater COVID-19 related mortality..

Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal phase II/III global study.

Written by | 29 Jul 2020

Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase II/III safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA… read more.

Health Canada approves Velkury to treat pneumonia associated with COVID-19. -Gilead Sciences

Written by | 29 Jul 2020

Health Canada has approved, with conditions, remdesivir (Velkury) from Gilead Sciences to treat COVID-19 patients. Remdesivir is used to treat those with pneumonia who need extra oxygen to… read more.

Phase III trial of mRNA 1273 in coronavirus expanded in US.- Moderna

Written by | 27 Jul 2020

Moderna announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late… read more.

Phase III results show antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of Covid-19 compared to placebo. – Glenmark Pharma

Written by | 26 Jul 2020

Glenmark announced Phase III results that showed its antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of COVID-19 compared to placebo . Favipiravir is a broad-spectrum oral… read more.

Trial of SNG 001 shows positive results in COVID-19 patients.- Synairgen

Written by | 21 Jul 2020

Synairgen announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. The double-blind placebo-controlled trial recruited 101 patients… read more.

Phase I/II COV001 trial of AZD 1222 shows vaccine well tolerated in SARS-CoV-2 virus.- AstraZeneca

Written by | 21 Jul 2020

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD 1222 vaccine, from AstraZeneca, was tolerated and generated robust immune responses against the… read more.

FDA approves phase II trial of AC 0010MA in COVID-19.- Sorrento Therapeutics

Written by | 21 Jul 2020

Sorrento Therapeutics received clearance from the FDA to initiate a Phase II trial of AC 0010MA (abivertinib) in patients with COVID-19 who have moderate to severe pulmonary symptoms…. read more.

Pfizer and BioNTech announce early positive update from German phase 1/II COVID-19 vaccine study, of BNT 162 mRNA-based vaccine, including first T cell response data.

Written by | 21 Jul 2020

BioNTech SE and Pfizer Inc announced initial data from their ongoing German Phase 1/II, open-label, non-randomized, non-placebo-controlled, dose-escalation trial , that is part of the global mRNA-based vaccine… read more.

FDA grants emergency use authorisation for xMAP SARS-CoV-2 Multi-Antigen IgG Assay in Coronavirus.- Luminex Corp

Written by | 21 Jul 2020

Luminex Corporation announced that the FDA has issued an Emergency Use Authorization (EUA) for the company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology… read more.

Heron Therapeutics announces initiation of phase II clinical study of Cinvanti for the treatment of COVID-19.

Written by | 18 Jul 2020

Heron Therapeutics announced the initiation of the GUARDS-1 Study, a Phase II clinical study evaluating Cinvanti (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19)…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.